Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ANCN

Anchiano Therapeutics (ANCN) Stock Price, News & Analysis

Anchiano Therapeutics logo

About Anchiano Therapeutics Stock (NASDAQ:ANCN)

Advanced Chart

Key Stats

Today's Range
$1.35
$1.43
50-Day Range
$2.82
$59.00
52-Week Range
$0.51
$10.55
Volume
138,918 shs
Average Volume
3.15 million shs
Market Capitalization
$10.54 million
P/E Ratio
9.47
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Receive ANCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anchiano Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANCN Stock News Headlines

ITeos Therapeutics Inc Ordinary Shares
Blackrock’s Sending THIS Crypto Higher on Purpose
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.
ENDV Endonovo Therapeutics, Inc.
See More Headlines

ANCN Stock Analysis - Frequently Asked Questions

Anchiano Therapeutics Ltd. (NASDAQ:ANCN) announced its earnings results on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.12.

Anchiano Therapeutics (ANCN) raised $35 million in an initial public offering on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Anchiano Therapeutics investors own include BioCryst Pharmaceuticals (BCRX), Bionano Genomics (BNGO), Cheniere Energy (LNG), Ocugen (OCGN), Agenus (AGEN), Allena Pharmaceuticals (ALNA) and Aileron Therapeutics (ALRN).

Company Calendar

Last Earnings
8/05/2019
Today
5/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ANCN
CIK
N/A
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Trailing P/E Ratio
9.47
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-27,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.01 per share
Price / Book
0.71

Miscellaneous

Free Float
N/A
Market Cap
$10.54 million
Optionable
Not Optionable
Beta
0.93
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ANCN) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners